Document Type

Article

Publication Date

6-27-2017

Abstract

Pembrolizumab is a Programmed Death 1 (PD-1) inhibitor used to treat advanced malignant melanoma and metastatic non-small cell lung cancer. It causes various endocrinological side effects including immune mediated thyroiditis. Thyroiditis caused by Pembrolizumab can mimic other immune mediated thyroiditis like Hashimoto thyroiditis and Grave’s disease.

Publication Title

Journal of Internal Medicine and Patient Care

First Page

107

Last Page

107

Share

COinS